The LINQ II ICM is the first continuous, long-term cardiac monitor cleared by FDA for the pediatric patient population DUBLIN, Sept. 20, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader ...

SonarMed™ Airway Monitoring System Continuously Checks for Endotracheal Tube Obstruction and Position for Neonates and Infants Providing Immediate, Actionable Intelligence for Clinicians DUBLIN, May ...

New Offerings Available to Existing Medtronic Care Management Services Customers as well as New Hospital Systems, Health Plans and Employers “With the rapid spread of COVID-19, we know that ...

Medtronic (NYSE:MDT) said it has received European approval for its disposable continuous glucose monitor, the MidiMed 780G system with Simplera Sync sensor. The medical device maker said it was the ...

Medtronic has its heart set on ensuring that its insertable cardiac monitors are as accurate as possible, and a new pair of artificial intelligence algorithms might be just the ticket. The AccuRhythm ...

MINNEAPOLIS and SAN FRANCISCO – Medtronic, Inc. today announced findings from the DISCERN AF trial, which utilized Medtronic’s Reveal® XT insertable cardiac monitor to conduct long-term monitoring to ...

Medtronic's Reveal XT subcutaneous cardiac monitor is now commercially available in the U.S. The company introduced Reveal XT in Europe in July of 2007. The device helps physicians diagnose heart ...

BRAMPTON, ON-- Medtronic of Canada today announced it has received Health Canada license for the Reveal LINQ Insertable Cardiac Monitor (ICM), the smallest implantable cardiac monitoring device ...

Clinicians have been able to remotely monitor pacemakers for years thanks to a combination of near-field and remote wireless technologies, but until now, patients haven’t been able to access the data ...

After receiving the necessary regulatory approval, Medtronic is launching its latest product on the global market. The medical devices company announced on Wednesday that it has received clearance ...

It started with black bears. It was 1999, and University of Minnesota researcher Paul Iaizzo connected with Tim Laske, now vice president of research in Medtronic's cardiac ablation products business.